Figure 1 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446

Figure 1 In vivo experiment: groups of EMT-6/P and EMT-6/V inoculated mice, Treatment approaches were: baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), and vincristine (2 mg/kg/every other day). The same concentrations were used in the combination treatment and triple therapy.